Isolation of a nanomolar scFv inhibiting the endopeptidase activity of botulinum toxin A, by single-round panning of an immune phage-displayed library of macaque origin

BMC Biotechnology

Volumn 11, Issue , 2011, Pages

  Chahboun, Siham ^a   Hust, Michael ^b   Liu, Yvonne ^c   Pelat, Thibaut ^a   Miethe, Sebastian ^b   Helmsing, Saskia ^b   Jones, Russell G A ^c   Sesardic, Dorothea ^c   Thullier, Philippe ^a  

^a INSTITUT DE RECHERCHE BIOMÉDICALE DES ARMÉES   (France)

^b TECHNICAL UNIVERSITY OF BRAUNSCHWEIG   (Germany)

^c NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY FRAGMENT; BIOLOGICAL AGENTS; BOTULINUM NEUROTOXINS; BOTULINUM TOXIN A; CLINICAL DEVELOPMENT; FOOD POISONING; GERMLINE GENES; HEAVY CHAIN; HYBRIDOMA TECHNOLOGY; IN-VITRO; IN-VIVO; LIGHT CHAIN; NANOMOLAR; NON-HUMAN PRIMATE; SEQUENCE ENCODING; THERAPEUTIC POTENTIALS; TOXIC SUBSTANCES;

BIOLOGICAL WEAPONS; ENCODING (SYMBOLS); GENES; IMMUNIZATION; MAMMALS;

ANTIBODIES;

BOTULINUM TOXIN A; PROTEINASE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ARTICLE; ASPERGILLUS FUMIGATUS; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME ISOLATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC SCREENING; HUMAN; MACACA FASCICULARIS; NONHUMAN; PROTEIN BINDING; PROTEIN ISOLATION;

ANIMALS; ANTIBODY AFFINITY; BOTULINUM TOXINS, TYPE A; ENDOPEPTIDASES; MACACA; PEPTIDE LIBRARY; SINGLE-CHAIN ANTIBODIES;

MACACA FASCICULARIS; PRIMATES;

EID: 81555230398     PISSN: None     EISSN: 14726750     Source Type: Journal    
DOI: 10.1186/1472-6750-11-113     Document Type: Article

References (45)

1. Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Hauer J, Layton M, et al. Botulinum toxin as a biological weapon: medical and public health management. Jama 2001, 285:1059-1070.
2. Gill DM. Bacterial toxins: a table of lethal amounts. Microbiol Rev 1982, 46:86-94.
3. Lim EC, Seet RC. Use of botulinum toxin in the neurology clinic. Nat Rev Neurol 2010, 6:624-636.
4. Smith LA. Botulism and vaccines for its prevention. Vaccine 2009, 27(Suppl 4):D33-39.
5. DasGupta BR. Botulinum and tetanus neurotoxins: neurotransmission and biomedical aspects 1993, New York: Plenum Press.
6. Black RE, Gunn RA. Hypersensitivity reactions associated with botulinal antitoxin. Am J Med 1980, 69:567-570.
7. Nowakowski A, Wang C, Powers DB, Amersdorfer P, Smith TJ, Montgomery VA, Sheridan R, Blake R, Smith LA, Marks JD. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci USA 2002, 99:11346-11350.
8. Razai A, Garcia-Rodriguez C, Lou J, Geren IN, Forsyth CM, Robles Y, Tsai R, Smith TJ, Smith LA, Siegel RW, et al. Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin type A. J Mol Biol 2005, 351:158-169.
9. Kalb SR, Lou J, Garcia-Rodriguez C, Geren IN, Smith TJ, Moura H, Marks JD, Smith LA, Pirkle JL, Barr JR. Extraction and inhibition of enzymatic activity of botulinum neurotoxins/A1, /A2, and /A3 by a panel of monoclonal anti-BoNT/A antibodies. Plos one 2009, 4:e5355.
10. Conway JO, Sherwood LJ, Collazo MT, Garza JA, Hayhurst A. Llama single domain antibodies specific for the 7 botulinum neurotoxin serotypes as heptaplex immunoreagents. Plos one 2010, 5:e8818.
11. Amersdorfer P, Wong C, Chen S, Smith T, Deshpande S, Sheridan R, Finnern R, Marks JD. Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries. Infect Immun 1997, 65:3743-3752.
12. Dolimbek BZ, Aoki KR, Steward LE, Jankovic J, Atassi MZ. Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A. Mol Immunol 2007, 44:1029-1041.
13. Kozaki S, Miki A, Kamata Y, Ogasawara J, Sakaguchi G. Immunological characterization of papain-induced fragments of Clostridium botulinum type A neurotoxin and interaction of the fragments with brain synaptosomes. Infect Immun 1989, 57:2634-2639.
14. Cheng LW, Stanker LH, Henderson TD, Lou J, Marks JD. Antibody protection against botulinum neurotoxin intoxication in mice. Infect Immun 2009, 77:4305-4313.
15. Adekar SP, Takahashi T, Jones RM, Al-Saleem FH, Ancharski DM, Root MJ, Kapadnis BP, Simpson LL, Dessain SK. Neutralization of botulinum neurotoxin by a human monoclonal antibody specific for the catalytic light chain. Plos one 2008, 3:e3023.
16. Dong J, Thompson AA, Fan Y, Lou J, Conrad F, Ho M, Pires-Alves M, Wilson BA, Stevens RC, Marks JD. A single-domain llama antibody potently inhibits the enzymatic activity of botulinum neurotoxin by binding to the non-catalytic alpha-exosite binding region. J Mol Biol 2010, 397:1106-1118.
17. Chassagne S, Laffly E, Drouet E, Herodin F, Lefranc MP, Thullier P. A high-affinity macaque antibody Fab with human-like framework regions obtained from a small phage display immune library. Mol Immunol 2004, 41:539-546.
18. Laffly E, Danjou L, Condemine F, Vidal D, Drouet E, Lefranc MP, Bottex C, Thullier P. Selection of a macaque Fab with framework regions like those in humans, high affinity, and ability to neutralize the protective antigen (PA) of Bacillus anthracis by binding to the segment of PA between residues 686 and 694. Antimicrob Agents Chemother 2005, 49:3414-3420.
19. Pelat T, Hüst M, Laffly E, Condemine F, Bottex C, Vidal D, Lefranc MP, Dübel S, Thullier P. High-affinity, human antibody-like antibody fragment (single-chain variable fragment) neutralizing the lethal factor (LF) of Bacillus anthracis by inhibiting protective antigen-LF complex formation. Antimicrob Agents Chemother 2007, 51:2758-2764.
20. Pelat T, Hüst M, Hale M, Lefranc MP, Dübel S, Thullier P. Isolation of a human-like antibody fragment (scFv) that neutralizes ricin biological activity. BMC Biotechnol 2009, 9:60.
21. Schütte M, Thullier P, Pelat T, Wezler X, Rosenstock P, Hinz D, Kirsch MI, Hasenberg M, Frank R, Schirrmann T, et al. Identification of a putative Crf splice variant and generation of recombinant antibodies for the specific detection of Aspergillus fumigatus. PLoS One 2009, 4:e6625.
22. Pelat T, Bedouelle H, Rees AR, Crennell SJ, Lefranc MP, Thullier P. Germline humanization of a non-human primate antibody that neutralizes the anthrax toxin, by in vitro and in silico engineering. J Mol Biol 2008, 384:1400-1407.
23. Pelat T, Thullier P. Non-human primate immune libraries combined with germline humanization: an (almost) new, and powerful approach for the isolation of therapeutic antibodies. Mabs 2009, 1:377-381.
24. Thullier P, Huish O, Pelat T, Martin AC. The humanness of macaque antibody sequences. J Mol Biol 2010, 396:1439-1450.
25. Abbas AK, Lichtman AH, Pillai S. Cellular and molecular immunology. 2007, Philadelphia: Saunders Elsevier, 6.
26. Thullier P, Chahboun S, Pelat T. A comparison of human and macaque (Macaca mulatta) immunoglobulin germline V regions and its implications for antibody engineering. Mabs 2010, 2:528-538.
27. Hill KK, Smith TJ, Helma CH, Ticknor LO, Foley BT, Svensson RT, Brown JL, Johnson EA, Smith LA, Okinaka RT, et al. Genetic diversity among Botulinum Neurotoxin-producing clostridial strains. J Bacteriol 2007, 189:818-832.
28. Heng BC, Cao T. Making cell-permeable antibodies (Transbody) through fusion of protein transduction domains (PTD) with single chain variable fragment (scFv) antibodies: potential advantages over antibodies expressed within the intracellular environment (Intrabody). Med Hypotheses 2005, 64:1105-1108.
29. Takahashi T, Joshi SG, Al-Saleem F, Ancharski D, Singh A, Nasser Z, Simpson LL. Localization of the sites and characterization of the mechanisms by which anti-light chain antibodies neutralize the actions of the botulinum holotoxin. Vaccine 2009, 27:2616-2624.
30. Pelat T, Hüst M, Thullier P. Obtention and engineering of non-human primate (NHP) antibodies for therapeutics. Mini Rev Med Chem 2009, 9:1633-1638.
31. Thanongsaksrikul J, Srimanote P, Maneewatch S, Choowongkomon K, Tapchaisri P, Makino S, Kurazono H, Chaicumpa W. A V H H that neutralizes the zinc metalloproteinase activity of botulinum neurotoxin type A. J Biol Chem 2010, 285:9657-9666.
32. Finnern R, Pedrollo E, Fisch I, Wieslander J, Marks JD, Lockwood CM, Ouwehand WH. Human autoimmune anti-proteinase 3 scFv from a phage display library. Clin Exp Immunol 1997, 107:269-281.
33. Kulkeaw K, Sakolvaree Y, Srimanote P, Tongtawe P, Maneewatch S, Sookrung N, Tungtrongchitr A, Tapchaisri P, Kurazono H, Chaicumpa W. Human monoclonal ScFv neutralize lethal Thai cobra, Naja kaouthia, neurotoxin. J Proteomics 2009, 72:270-282.
34. Hunt AR, Frederickson S, Hinkel C, Bowdish KS, Roehrig JT. A humanized murine monoclonal antibody protects mice either before or after challenge with virulent Venezuelan equine encephalomyelitis virus. J Gen Virol 2006, 87:2467-2476.
35. Goodchild SA, O'Brien LM, Steven J, Muller MR, Lanning OJ, Logue CH, D'Elia RV, Phillpotts RJ, Perkins SD. A humanised murine monoclonal antibody with broad serogroup specificity protects mice from challenge with Venezuelan equine encephalitis virus. Antiviral Res 2011, 90:1-8.
36. Hu WG, Phelps AL, Jager S, Chau D, Hu CC, O'Brien LM, Perkins SD, Gates AJ, Phillpotts RJ, Nagata LP. A recombinant humanized monoclonal antibody completely protects mice against lethal challenge with Venezuelan equine encephalitis virus. Vaccine 2010, 28:5558-5564.
37. Hüst M, Meyer T, Voedisch B, Rülker T, Thie H, El-Ghezal A, Kirsch MI, Schütte M, Helmsing S, Meier D, et al. A human scFv antibody generation pipeline for proteome research. J Biotechnol 2011, 152:159-170.
38. Kirsch MI, Hülseweh B, Nacke C, Rülker T, Schirrmann T, Marschall HJ, Hüst M, Dübel S. Development of human antibody fragments using antibody phage display for the detection and diagnosis of Venezuelan equine encephalitis virus (VEEV). BMC Biotechnol 2008, 8:66.
39. Rondot S, Koch J, Breitling F, Dübel S. A helper phage to improve single-chain antibody presentation in phage display. Nat Biotechnol 2001, 19:75-78.
40. Soltes G, Hüst M, Ng KK, Bansal A, Field J, Stewart DI, Dübel S, Cha S, Wiersma EJ. On the influence of vector design on antibody phage display. J Biotechnol 2007, 127:626-637.
41. Barbas CF. Phage display: a laboratory manual 2001, Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.
42. Karlsson R, Michaelsson A, Mattsson L. Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system. J Immunol Methods 1991, 145:229-240.
43. Schuck P, Minton AP. Analysis of mass transport-limited binding kinetics in evanescent wave biosensors. Anal Biochem 1996, 240:262-272.
44. Abhinandan KR, Martin AC. Analyzing the "degree of humanness" of antibody sequences. J Mol Biol 2007, 369:852-862.
45. Jones RG, Ochiai M, Liu Y, Ekong T, Sesardic D. Development of improved SNAP25 endopeptidase immuno-assays for botulinum type A and E toxins. J Immunol Methods 2008, 329:92-101.